| Literature DB >> 29322009 |
S Nurdiana1,2, Y M Goh2, A Hafandi2, S M Dom3, A Nur Syimal'ain1, N M Noor Syaffinaz1, M Ebrahimi2.
Abstract
Despite the fact that Ficus deltoidea and vitexin played important roles in controlling hyperglycemia, an effective mitigation strategy dealing with cognitive deficit observed in diabetes, little is known about its neuroprotective effects. The study is aimed to determine changes in behavioral, gyrification patterns and brain oxidative stress markers in streptozotocin (STZ)-induced diabetic rats following F. deltoidea and vitexin treatments. Diabetic rats were treated orally with metformin, methanolic extract of F. deltoidea leaves and vitexin for eight weeks. Morris water maze (MWM) test was performed to evaluate learning and memory functions. The patterns of cortical gyrification were subsequently visualized using micro-computed tomography (micro-CT). Quantification of brain oxidative stress biomarkers, insulin, amylin as well as serum testosterone were measured using a spectrophotometer. The brain fatty acid composition was determined using gas chromatography (GC). Biochemical variation in brain was estimated using Fourier transform infrared (FT-IR) spectroscopy. Results showed that oral administration of F. deltoidea extract and vitexin to diabetic rats attenuated learning and memory impairment, along with several clusters of improved gyrification. Both treatments also caused a significant increase in the superoxide dismutase (SOD) and glutathione peroxidase (GPx) values, as well as a significant reduction of TBARS. Strikingly, improvement of cortical gyrification, spatial learning and memory are supported by serum testosterone levels, fatty acid composition of brain and FT-IR spectra.Entities:
Keywords: Cognition; Diabetes; F. deltoidea; Gyrification; Micro-computed tomography; Vitexin
Year: 2017 PMID: 29322009 PMCID: PMC5755998 DOI: 10.1016/j.jtcme.2017.05.006
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Depiction of different starting positions in each trail.
| Day | Trial 1 | Trial 2 | Trial 3 |
|---|---|---|---|
| 1 | E | SE | NW |
| 2 | N | NW | E |
| 3 | SE | E | N |
| 4 | E | NW | N |
| 5 | SE | E | NW |
| 6 (probe trial) | NE |
Effect of F. deltoidea and vitexin on fasting blood glucose level (mmol/L) in STZ induced diabetic rats.
| Groups | Fasting blood glucose (mmol/L) ± SD | % changes | |
|---|---|---|---|
| Before | After | ||
| NC | 4.80 ± 0.30a | 4.93 ± 0.21a | +2.71% |
| DC | 20.00 ± 3.24b | 30.13 ± 2.63b | +50.65% |
| DMET | 29.30 ± 3.70c | 19.83 ± 3.75c | −32.32% |
| DFD | 27.87 ± 6.03c | 17.27 ± 4.97c | −38.03% |
| DV | 30.43 ± 4.07c | 15.87 ± 2.01c | −47.85% |
Values are mean ± 1 SD for 6 rats in each group. Values with different superscripts down the column indicate significant difference at p < 0.05.
Fig. 1Effects of 8 weeks daily of administration of . Day 1- rats were oriented to the maze; Day 2- rats learned to locate the visible platform; Day 3 to 5-rats learned to locate the hidden platform from different or randomized quadrants. Values with different superscripts are significantly different at p < 0.05.
Changes during probe trial of various experimental groups.
| Groups | Escape latency times (s) | Mean path length (m) | % of time spent in the target quadrant | Swimming speed (ms−1) |
|---|---|---|---|---|
| NC | 6.97 ± 2.12a | 1.84 ± 0.46a | 33.41 ± 2.99c | 0.267 ± 0.021ab |
| DC | 42.57 ± 2.58c | 8.79 ± 0.33d | 14.04 ± 1.68a | 0.212 ± 0.002a |
| DMET | 10.67 ± 2.08a | 3.25 ± 1.13b | 23.23 ± 2.73b | 0.299 ± 0.045b |
| DFD | 18.87 ± 10.74b | 5.19 ± 2.62c | 12.44 ± 2.56a | 0.280 ± 0.031ab |
| DV | 9.34 ± 0.85a | 3.1 ± 0.26b | 16.56 ± 1.16a | 0.334 ± 0.005b |
Data are presented as mean ± 1SD. Values with different superscripts in a column differed significantly at p < 0.05.
Fig. 2Cross-sectional micro-CT images of rat brain. Gyrification abnormalities were observed in the DC and DMET while a clear deep sulcal lines obtained in the cortex of DFD and DV rats. NC: Normal control; DC: diabetic control; DMET: diabetic treated with metformin; DFD: diabetic treated with F. deltoidea; DV: diabetic treated with vitexin; L: left hemisphere and R: right hemisphere. Images are representative of three animals per experimental group.
Oxidative stress marker and antioxidant enzymes of different experimental groups.
| Groups | Oxidative stress marker | Antioxidant enzymes | |
|---|---|---|---|
| TBARS (nmol MDA/mg protein) | GPx (U/mg protein) | SOD (mU/mg protein) | |
| NC | 1.61 ± 0.109a | 25.03 ± 0.371b | 13.02 ± 0.891d |
| DC | 44.15 ± 9.655c | 21.69 ± 5.223b | 2.61 ± 0.363a |
| DMET | 20.95 ± 2.493b | 24.09 ± 2.538b | 4.45 ± 0.413b |
| DFD | 10.74 ± 0.662ab | 42.13 ± 0.702c | 6.94 ± 0.663c |
| DV | 9.55 ± 0.385ab | 13.40 ± 3.255a | 4.89 ± 0.208b |
Data are presented as mean ± 1SD. Values with different superscripts in a column differed significantly at p < 0.05.
Insulin, amylin and testosterone concentrations of different experimental groups.
| Groups | Insulin (pg/ml) | Amylin (ng/ml) | Testosterone (ng/ml) |
|---|---|---|---|
| NC | 63.15 ± 0.936d | 40.87 ± 1.162b | 1.81 ± 0.088ab |
| DC | 39.13 ± 0.254b | 35.02 ± 0.702a | 0.84 ± 0.370a |
| DMET | 50.25 ± 0.718c | 33.15 ± 4.442a | 2.97 ± 0.627c |
| DFD | 34.99 ± 0.369a | 32.25 ± 0.913a | 2.40 ± 0.166bc |
| DV | 89.49 ± 1.279e | 45.60 ± 0.860b | 3.03 ± 0.436c |
Data are presented as mean ± 1SD. Different superscripts in a column differed significantly at p < 0.05.
Fatty acid composition (percentage of total identified fatty acids) of the brain of the experimental groups.a
| Fatty acids composition (%) | Groups | ||||
|---|---|---|---|---|---|
| NC | DC | DMET | DFD | DV | |
| Palmitic acid (C16:0) | 14.11 ± 2.41 | 19.07 ± 1.21 | 17.98 ± 2.17 | 15.01 ± 5.59 | 20.58 ± 1.79 |
| Heptadecanoic acid (C17:0) | 1.63 ± 2.30 | 4.31 ± 0.04 | 4.32 ± 0.690 | 2.32 ± 2.714 | 4.13 ± 0.183 |
| Stearic acid (C18:0) | 13.09 ± 2.26 | 19.12 ± 0.82 | 17.09 ± 2.07 | 14.73 ± 5.71 | 18.36 ± 1.30 |
| Total SFA | 28.82 ± 6.97 | 42.50 ± 1.71 | 39.39 ± 4.93 | 32.06 ± 12.76 | 43.06 ± 1.97 |
| Oleic acid (C18:1n9) | 14.91 ± 2.15 | 29.06 ± 2.13 | 23.15 ± 7.95 | 19.96 ± 8.26 | 27.91 ± 0.65 |
| Total MUFA | 14.91 ± 2.15 | 29.06 ± 2.13 | 23.15 ± 7.95 | 19.96 ± 8.26 | 27.91 ± 0.65 |
| Linoleic acid (C18:2n6) | 0.00 ± 0.00 | 2.39 ± 2.08 | 2.14 ± 1.18 | 1.45 ± 1.34 | 4.03 ± 1.94 |
| Arachidonic acid (C20:4n6) | 5.80 ± 1.30 | 8.05 ± 0.75 | 8.03 ± 0.55 | 6.64 ± 2.62 | 8.58 ± 0.45 |
| total n-6 PUFA | 5.80 ± 1.30a | 10.43 ± 2.23bc | 10.17 ± 0.63bc | 8.09 ± 2.71ab | 12.60 ± 1.60c |
| α-Linolenic acid (C18:3n3) | 43.35 ± 14.63c | 6.92 ± 2.28a | 15.66 ± 12.86ab | 31.70 ± 7.42bc | 4.31 ± 1.54a |
| Docosapentaenoic acid (C22:5n3) | 1.09 ± 1.55a | 3.19 ± 0.17b | 3.36 ± 0.16b | 2.09 ± 0.96ab | 3.21 ± 0.12b |
| Docosahexaenoic acid (C22:6n3) | 6.02 ± 2.66 | 7.90 ± 1.42 | 8.27 ± 0.81 | 7.30 ± 3.64 | 8.90 ± 0.65 |
| Total n-3 PUFA | 50.46 ± 10.42b | 18.01 ± 1.03a | 27.29 ± 13.51a | 41.10 ± 3.65b | 16.43 ± 1.66a |
| n-6: n-3 | 0.12 ± 0.05a | 0.59 ± 0.16bc | 0.43 ± 0.24abc | 0.32 ± 0.30ab | 0.78 ± 0.15c |
Values are mean ± 1 SD at n = 3. Values with different superscripts in a row differed significantly at p < 0.05.
The data are expressed as the percentage of total identified fatty acids.
Fig. 3Second derivative spectra for brain tissue in the regions of 3000–2800 cm−1.
Fig. 4Second derivative spectra for brain tissue in the regions of 1450–1390 cm−1.
Fig. 5Second derivative spectra 5 for brain tissue in the regions of 1180–1110 cm−1.